Global Reports Inside NYC Cannabis Convention Include: Open Availability of Low THC Hemp Oil, New York’s Growing Medical Marijuana Business Landscape, and 5-Year-Old Cannabis Consumer
SAN DIEGO, June 23, 2015 (GLOBE NEWSWIRE) — As New York prepares for access to medical cannabis, many entrepreneurs curious about establishing businesses in support of the historic statewide initiative turned out at the Cannabis World Congress and Business Expo at Javits Center in Manhattan. There, Medical Marijuana, Inc.‘s (OTC Pink: MJNA) HempMeds® and investment portfolio company, KannaLife Sciences, were featured in media reports by CBS News, NBC New York, Fox 5 New York, PIX11, Yahoo News, Yahoo Finance, Getty Images and more.
Marijuana products are not yet available in New York and, as Fox 5 New York reported, the statewide program will begin on January 5, 2016. However, hemp oil products from HempMeds® are readily available and shipping to all 50 states. On display for conference attendees and members of the news media were hemp oil product samples including:
Real Scientific Hemp Oil™ (RSHO™) – concentrated hemp oil
Dixie Botanicals™ – concentrated hemp oil tinctures, capsules and salve
HempVAP® – interchangeable hemp oil cartridges and electronic vaporizer pen
DEFINED Transformation – luxury, all-natural herbal extracts for anti-aging skin care with hemp oil
Kannactiv by KannaLife – all-natural botanicals with hemp oil for troubled skin
“We are grateful to the global press and to the International Cannabis Association for serving as an effective platform to raise awareness and educate media audiences around the world,” states Andrew Hard, CEO of CMW Media and spokesperson for HempMeds®. “Through coverage of the New York Cannabis Convention, viewers worldwide have a much better understanding of the power of hemp oil and cannabis products as well as ancillary businesses that will shape and support the rapidly growing industry. We would also like to express our sincere appreciation for Mr. Craig Pagano for taking time out of his week to share the profile of one of New York’s youngest low THC cannabis hemp oil consumers: his 5-year-old daughter Beyla.”
Long Island-based KannaLife Sciences (“KannaLife”), an MJNA portfolio investment company, is on the leading edge of the medical marijuana and cannabis industry. KannaLife holds an exclusive license from the National Institutes of Health to develop cannabis-based orphan drugs for chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE) in conjunction with the U.S. Department of Health and Human Service’s Patent 6630507. The Company, recently featured in CNN’s Weed 3: The Marijuana Revolution,is working to develop a cannabis-based solution for CTE that provides hope to professional and collegiate athletes, youth sports team members, members of the armed forces and those affected by a traumatic brain injury.
KannaLife was a featured guest speaker and informed attendees on cannabidiol (CBD) at the NYC Cannabis Conference. The Company was featured in multiple interviews including Fox 5 New York, NBC New York and CBS News reports.
Photos accompanying this release are available at
For more information on HempMeds and their all-natural hemp oil products, visit: www.hempmeds.com. The Company invites the public to get involved in the conversation of the expanding cannabis industry with HempMeds® through the Company’s social media websites on Facebook and Twitter.
HempMeds® offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMeds® is the communication hub for the Medical Marijuana Inc. portfolio of companies.
About KannaLife Sciences, Inc.
KannaLife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. KannaLife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit KannaLife.com.
About Medical Marijuana Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Public Relations contact:
GH Investment Advisors
550 West “C” Street, Ste. 2040
San Diego, CA 92101
Office: (858) 264-6500
Toll Free: (877) 964-6463